
    
      This is a randomized, double blind, placebo-controlled antidepressant augmentation trial. All
      participants are randomly divided into 3 groups treated orally with "escitalopram +
      golimumab" (N = 60), "escitalopram + calcium tablet" (N = 60) or "escitalopram +placebo" (N =
      60).
    
  